Por Renan Filho · 2026-10-01**Lead**
The American Kratom Association (AKA) has issued a stark warning to the U.S. sports community: synthetic opioids, often sold as dietary supplements or “legal highs,” are increasingly being marketed under the name “kratom,” creating a dangerous confusion that could lead to failed drug tests, health emergencies, and stricter bans on the natural plant. The warning comes as several state legislatures and collegiate athletic conferences consider new regulations on kratom, a tropical tree leaf traditionally used for mild stimulant and pain-relief effects. The AKA stresses that genuine kratom is not an opioid, but the mislabeling of synthetic compounds as “kratom” threatens the safety of athletes and the reputation of the legitimate kratom industry.
**Context**
Kratom (Mitragyna speciosa) has been used for centuries in Southeast Asia and has gained popularity in the United States as an alternative for pain management and energy. Unlike synthetic opioids, kratom’s active compounds—mitragynine and 7-hydroxymitragynine—interact with opioid receptors but are not classified as opioids by the U.S. Drug Enforcement Administration (DEA), though the agency has listed kratom as a “drug of concern.” The AKA has long advocated for responsible regulation of kratom products, including Good Manufacturing Practices (GMP) standards. However, in recent years, a growing number of unregulated products containing synthetic opioids—such as tianeptine, a drug not approved for any medical use in the U.S.—have been sold online and in smoke shops under names like “kratom extract,” “kratom alternative,” or simply “kratom.” These synthetic compounds can cause severe respiratory depression, addiction, and overdose, risks far beyond those associated with natural kratom.
For the sports world, the issue is particularly acute. The National Collegiate Athletic Association (NCAA) and many professional leagues, including the NFL and MLB, have banned kratom outright, citing concerns about safety and potential performance-enhancing effects. Yet the mislabeling of synthetic opioids as kratom creates a loophole: athletes who intentionally or inadvertently consume these synthetic products may test positive for substances that are not even kratom, leading to suspensions, loss of scholarships, or career damage. Moreover, the presence of dangerous synthetic opioids in the supplement market undermines the credibility of all natural products, prompting calls for even stricter bans that would also affect legitimate kratom users.
**Análise**
The AKA’s warning is not merely a public health announcement—it is a strategic move to protect the legal status of kratom in the face of mounting regulatory pressure. By drawing a clear line between natural kratom and synthetic impostors, the industry hopes to persuade lawmakers and sports authorities to target the counterfeit products rather than the plant itself. This distinction is critical because several states, including Alabama, Arkansas, and Indiana, have already banned kratom, while others are considering similar measures. If sports organizations conflate synthetic opioids with kratom, they could inadvertently strengthen the case for a federal ban, which the AKA has fought for years.
For athletes, the implications are immediate. The supplement market is notoriously underregulated, and many products labeled as “kratom” or “kratom blends” may contain undisclosed synthetic opioids. Without rigorous third-party testing, an athlete cannot be certain of what they are consuming. The AKA has called on the NCAA and the U.S. Anti-Doping Agency (USADA) to update their prohibited lists to explicitly name synthetic opioids like tianeptine, rather than relying on broad categories that include kratom. This would allow athletes to avoid genuine kratom if they choose, while ensuring that those who use it responsibly are not penalized for the actions of bad actors.
**Fontes**
This article is based on public statements and reports from the American Kratom Association, including their official position papers and press releases regarding synthetic opioid mislabeling. Additional context was drawn from the U.S. Drug Enforcement Administration’s public information on kratom and synthetic opioids, as well as published reports from the NCAA and USADA on banned substances. No individual interviews were conducted; all information is derived from verifiable, publicly available sources.